Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90–95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects. The major histologic RCC subtype is ccRCC, which represents 80–95% of cases (as shown in Table 2). Other forms of the disease, usually referred as non-clear cell RCC (nccRCC), include papillary RCC (PRCC), chromophobe RCC (ChRCC), translocation carcinoma, medullary carcinoma, and collecting duct carcinoma. At present, metastatic RCC (mRCC) is considered incurable, with only a small minority of patients achieving a complete response (CR) to treatment. However, major advances in the treatment landscape within the past 15 years have significantly improved progression-free survival (PFS) and overall survival (OS).
GlobalData is expecting a total of 7 new entrants to launch over the forecast period in the 8MM from 2018–2028 while specific marketed agents are expected to undergo label expansion. The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in fist-line treatment of metastatic RCC. No drugs are currently in late development for nccRCC leaving the treatment of that population an unmet need within the forecast period.
KEY QUESTIONS ANSWERED
Seven late-stage pipeline agents are going to enter the renal cell carcinoma market from 2018 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
What are the current unmet needs in renal cell carcinoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
What is the market outlook in the 8MM from 2018-2028? Consideration of major patent expiries, launch of new premium priced agents and expected label expansions.
What are the main corporate trends? Who are the current and future players?

Scope

Overview of renal cell carcinoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline renal cell carcinoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting renal cell carcinoma therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global renal cell carcinoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated approval and launch of 7 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.

The main barriers to growth in the 8MM include the patent expiry of major brands and the short sales opportunity window due to the aggressiveness of the disease.

Among the late-stage pipeline products and marketed agents, TKI inhibitors and immune checkpoint inhibitors are expected to generate the greatest revenues over the forecast period.

The two most important unmet needs in the renal cell carcinoma market include: improved treatments that increase complete response rates and treatment options for refractory patients.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global renal cell carcinoma market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the renal cell carcinoma therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Altor Biosciences
Aveo Pharma
Bayer
Calithera Biosciences
Xynomic Pharmaceuticals
Eisai
Merck kGaA
AstraZeneca
Betta Pharmaceuticals
Bristol-Myers-Squibb
Exelixis
Merck & Co.
Nektar Therapeutics
Novartis
Pfizer
Roche

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Renal Cell Carcinoma: Executive Summary

2.1 The RCC market is expected to grow to $7.4B in 2028

2.2 The Development of Combination Treatments Is the Pillar of Corporate Strategies in RCC

2.3 Opportunities Remain for More Effective Therapies and Treatments for nccRCC

2.4 The RCC Pipeline Is Diverse, Comprising Label Expansions and Novel Mechanisms of Action

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Prognostic models

4.3 Biomarkers

4.4 Clinical Staging

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods, Population

5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC

5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Stage at Diagnosis

5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Prognostic Model

5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Biomarkers

5.4.7 Forecast Assumptions and Methods, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC

5.5 Epidemiological Forecast for RCC (2018–2028)

5.5.1 Diagnosed Incident Cases of RCC

5.5.2 Age-Specific Diagnosed Incident Cases of RCC

5.5.3 Sex-Specific Diagnosed Incident Cases of RCC

5.5.4 Diagnosed Incident Cases of RCC by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of RCC Stage IV by Prognostic Model

5.5.6 Diagnosed Incident Cases of RCC Stage IV by Biomarkers

5.5.7 Five-Year Diagnosed Prevalent Cases of RCC

5.5.8 10-Year Diagnosed Prevalent Cases of RCC

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Available Treatments

6.2 US

6.2.1 Diagnosis

6.2.2 Clinical Practice

6.3 5EU

6.3.1 Diagnosis

6.3.2 Clinical Practice

6.4 Japan

6.4.1 Diagnosis

6.4.2 Clinical Practice

6.5 China

6.5.1 Diagnosis

6.5.2 Clinical Practice

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Improved Treatments that Increase Complete Response Rates in mRCC Patients

8.3 Treatment Options for Refractory Patients

8.4 Treatment of nccRCC

8.5 Effective Adjuvant Therapies

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.2.1 Immunotherapies

10.2.2 Combination treatments

10.2.3 Targeting Earlier Stages of the Disease

10.3 Pfizer’s Portfolio Assessment

10.4 Merck & Co.’s Portfolio Assessment

10.5 Bristol-Myers Squibb’s Portfolio Assessment

10.6 Exelixis’ Portfolio Assessment

10.7 Eisai’s Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic/Biosimilar Erosion

12.3.9 Pricing and clinical positioning of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: RCC: Key Metrics in the 8MM

Table 2: Classifications of RCC

Table 3: TNM and Staging Classification System for RCC

Table 4: Risk Factors and Comorbidities for RCC

Table 5: RCC Clinical Stages at Diagnosis

Table 6: Treatment Guidelines for RCC

Table 7: Country Profile – US

Table 8: Country Profile – 5EU

Table 9: Country Profile – Japan

Table 10: Leading Treatments for Disease RCC, 2019

Table 11: Pfizer’s RCC Portfolio Assessment, 2019

Table 12: Merck & Co.’s RCC Portfolio Assessment, 2019

Table 13: BMS’s RCC Portfolio Assessment, 2019

Table 14: Exelixis’ RCC Portfolio Assessment, 2019

Table 15: Eisai’s RCC Portfolio Assessment, 2019

Table 16: RCC Market – Global Drivers and Barriers, 2018–2028

Table 17: Key Events Impacting Sales for RCC in the US, 2018–2028

Table 18: RCC Market – Drivers and Barriers in the US, 2018–2028

Table 19: Key Events Impacting Sales for RCC in the 5EU, 2018–2028

Table 20: RCC Market – Drivers and Barriers in the 5EU, 2018–2028

Table 21: Key Events Impacting Sales for RCC in Japan, 2018–2028

Table 22: RCC Market – Global Drivers and Barriers in Japan, 2018–2028

Table 23: Key Events Impacting Sales for RCC in China, 2018–2028

Table 24: RCC Market – Global Drivers and Barriers in China, 2018–2028

Table 25: Key Historical and Projected Launch Dates for RCC

Table 26: Key Historical and Projected Patent Expiry Dates for RCC

Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for RCC in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in RCC During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of RCC During the Forecast Period

Figure 4: Key pathways and drug targets in RCC.

Figure 5: 8MM, Diagnosed Incidence of RCC, Men, Ages ≥18 Years, 2008–2028

Figure 6: 8MM, Diagnosed Incidence of RCC, Women, Ages ≥18 Years, 2008–2028

Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of RCC

Figure 8: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Stage at Diagnosis

Figure 9: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Prognostic Model

Figure 10: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of EGFR)

Figure 11: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of VEGF)

Figure 12: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of mTOR)

Figure 13: 8MM, Sources Used, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC

Figure 14: 8MM, Diagnosed Incident Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2018

Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥18 Years, N, 2018

Figure 17: 8MM, Diagnosed Incident Cases of RCC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2018

Figure 18: 8MM, Diagnosed Incident Cases of RCC Stage IV by Prognostic Model, Ages ≥18 Years, Both Sexes, N, 2018

Figure 19: 8MM, Diagnosed Incident Cases of RCC Stage IV by Biomarkers, Ages ≥18 Years, Both Sexes, N, 2018

Figure 20: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 21: 8MM, 10-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 22: Treatment Algorithm for advanced/metastatic RCC

Figure 23: Unmet Needs and Opportunities in RCC

Figure 24: Overview of the Development Pipeline in RCC, 2019

Figure 25: Pivotal Phase II/III Trials for the Promising RCC Pipeline Agents, 2019

Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents for RCC, 2018–2028

Figure 27: Analysis of the Company Portfolio Gap in RCC During the Forecast Period

Figure 28: Global (8MM) Sales Forecast by Country for RCC in 2018 and 2028

Figure 29: Sales Forecast by Class for RCC in the US in 2018 and 2028

Figure 30: Sales Forecast by Class for RCC in the 5EU in 2018 and 2028

Figure 31: Sales Forecast by Class for RCC in Japan in 2018 and 2028

Figure 32: Sales Forecast by Class for RCC in China in 2018 and 2028

Frequently asked questions

Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2028 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2028 in real time.

  • Access a live Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.